1955 related articles for article (PubMed ID: 32405156)
21. A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.
Duverger E; Herlem G; Picaud F
J Mol Graph Model; 2021 May; 104():107834. PubMed ID: 33516966
[TBL] [Abstract][Full Text] [Related]
22. Mass Spectrometry and Structural Biology Techniques in the Studies on the Coronavirus-Receptor Interaction.
Witkowska D
Molecules; 2020 Sep; 25(18):. PubMed ID: 32927621
[TBL] [Abstract][Full Text] [Related]
23. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
24. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
Robson B
Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of receptor recognition by SARS-CoV-2.
Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects.
Wrobel AG; Benton DJ; Xu P; Roustan C; Martin SR; Rosenthal PB; Skehel JJ; Gamblin SJ
Nat Struct Mol Biol; 2020 Aug; 27(8):763-767. PubMed ID: 32647346
[TBL] [Abstract][Full Text] [Related]
28. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D
Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381
[TBL] [Abstract][Full Text] [Related]
29. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor.
Yang Y; Du Y; Kaltashov IA
Anal Chem; 2020 Aug; 92(16):10930-10934. PubMed ID: 32678978
[TBL] [Abstract][Full Text] [Related]
30. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
[TBL] [Abstract][Full Text] [Related]
31. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
33. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
34. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
[TBL] [Abstract][Full Text] [Related]
35. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
36. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
[TBL] [Abstract][Full Text] [Related]
37. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H; Pillat MM
Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653
[TBL] [Abstract][Full Text] [Related]
38. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 host tropism: An in silico analysis of the main cellular factors.
Rangel HR; Ortega JT; Maksoud S; Pujol FH; Serrano ML
Virus Res; 2020 Nov; 289():198154. PubMed ID: 32918944
[TBL] [Abstract][Full Text] [Related]
40. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]